BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Urban S, Neumann-Haefelin C, Lampertico P. Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease. Gut 2021;70:1782-94. [PMID: 34103404 DOI: 10.1136/gutjnl-2020-323888] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 32.0] [Reference Citation Analysis]
Number Citing Articles
1 Burm R, Maravelia P, Ahlen G, Ciesek S, Caro Perez N, Pasetto A, Urban S, Van Houtte F, Verhoye L, Wedemeyer H, Johansson M, Frelin L, Sällberg M, Meuleman P. Novel prime-boost immune-based therapy inhibiting both hepatitis B and D virus infections. Gut 2022:gutjnl-2022-327216. [PMID: 35977815 DOI: 10.1136/gutjnl-2022-327216] [Reference Citation Analysis]
2 Degasperi E, Anolli MP, Uceda Renteria SC, Sambarino D, Borghi M, Perbellini R, Scholtes C, Facchetti F, Loglio A, Monico S, Fraquelli M, Costantino A, Ceriotti F, Zoulim F, Lampertico P. Bulevirtide monotherapy for 48 Weeks in hdv patients with compensated cirrhosis and clinically significant portal hypertension. J Hepatol 2022:S0168-8278(22)02980-4. [PMID: 35973578 DOI: 10.1016/j.jhep.2022.07.016] [Reference Citation Analysis]
3 Lucifora J, Verrier ER, Baumert TF. Inhibiting cell-to-cell transmission to reach HDV cure: The importance of IFN-α. J Hepatol 2022:S0168-8278(22)02978-6. [PMID: 35952820 DOI: 10.1016/j.jhep.2022.07.015] [Reference Citation Analysis]
4 Buti M. Hepatitis D virus: more attention needed. Nat Rev Gastroenterol Hepatol 2022. [PMID: 35883011 DOI: 10.1038/s41575-022-00664-0] [Reference Citation Analysis]
5 Dandri M, Volmari A, Lütgehetmann M. The hepatitis delta virus and chronic hepatitis D. J Hepatol 2022:S0168-8278(22)00337-3. [PMID: 35850738 DOI: 10.1016/j.jhep.2022.05.022] [Reference Citation Analysis]
6 Jachs M, Schwarz C, Panzer M, Binter T, Aberle SW, Hartl L, Dax K, Aigner E, Stättermayer AF, Munda P, Graziadei I, Holzmann H, Trauner M, Zoller H, Gschwantler M, Mandorfer M, Reiberger T, Ferenci P. Response-guided long-term treatment of chronic hepatitis D patients with bulevirtide-results of a "real world" study. Aliment Pharmacol Ther 2022;56:144-54. [PMID: 35514008 DOI: 10.1111/apt.16945] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
7 Soriano V, de Mendoza C, Treviño A, Ramos-Rincón JM, Moreno-Torres V, Corral O, Barreiro P. Treatment of Hepatitis Delta and HIV Infection. Liver Int 2022. [PMID: 35748639 DOI: 10.1111/liv.15345] [Reference Citation Analysis]
8 Lampertico P, Roulot D, Wedemeyer H. BULEVIRTIDE WITH OR WITHOUT PEGIFNα FOR PATIENTS WITH COMPENSATED CHRONIC HEPATITIS DELTA: FROM CLINICAL TRIALS TO REAL LIFE STUDIES. J Hepatol 2022:S0168-8278(22)00373-7. [PMID: 35752223 DOI: 10.1016/j.jhep.2022.06.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Pearlman BL. A Patient With Jaundice and Malaise. JAMA 2022. [PMID: 35696255 DOI: 10.1001/jama.2022.8384] [Reference Citation Analysis]
10 Ezquerra-Durán A, Gutiérrez-Cobos A, García-Buey L. Healing of chronic hepatitis delta relapsing to pegylated interferon with tenofovir. Med Clin (Barc) 2022:S0025-7753(22)00152-X. [PMID: 35659423 DOI: 10.1016/j.medcli.2022.02.017] [Reference Citation Analysis]
11 Huang Y, Qin A, Tsai C, Chen P. Novel Pegylated Interferon for the Treatment of Chronic Viral Hepatitis. Viruses 2022;14:1128. [DOI: 10.3390/v14061128] [Reference Citation Analysis]
12 Herta T, Hahn M, Maier M, Fischer J, Niemeyer J, Hönemann M, Böhlig A, Gerhardt F, Schindler A, Schumacher J, Berg T, Wiegand J, van Bömmel F. Efficacy and Safety of Bulevirtide plus Tenofovir Disoproxil Fumarate in Real-World Patients with Chronic Hepatitis B and D Co-Infection. Pathogens 2022;11:517. [DOI: 10.3390/pathogens11050517] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Papatheodoridi A, Papatheodoridis G. Hepatocellular carcinoma: the virus or the liver? Liver Int 2022. [PMID: 35319167 DOI: 10.1111/liv.15253] [Reference Citation Analysis]
14 Brillanti S. Management of Delta Hepatitis 45 Years after the Discovery of HDV. JCM 2022;11:1587. [DOI: 10.3390/jcm11061587] [Reference Citation Analysis]
15 Brancaccio G, Shanyinde M, Puoti M, Gaeta GB, Monforte AD, Vergori A, Rusconi S, Mazzarelli A, Castagna A, Antinori A, Cozzi-lepri A. Hepatitis delta coinfection in persons with HIV: misdiagnosis and disease burden in Italy. Pathogens and Global Health. [DOI: 10.1080/20477724.2022.2047551] [Reference Citation Analysis]
16 Schwarz C, Chromy D, Bangert C, Schwarz M, Jachs M, Reiberger T, Gschwantler M. Immediate-type hypersensitivity reaction to bulevirtide and successful desensitization in a patient with HBV/HDV-associated compensated cirrhosis. Journal of Hepatology 2022. [DOI: 10.1016/j.jhep.2022.03.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
17 Osiowy C, Swidinsky K, Haylock-jacobs S, Sadler MD, Fung S, Wong D, Minuk GY, Doucette KE, Wong P, Tam E, Cooper C, Ramji A, Ma M, Nudo C, Tsoi K, Coffin CS. Molecular epidemiology and clinical characteristics of hepatitis D virus infection in Canada. JHEP Reports 2022. [DOI: 10.1016/j.jhepr.2022.100461] [Reference Citation Analysis]
18 Oberhardt V, Hofmann M, Thimme R, Neumann-haefelin C. Adaptive Immune Responses, Immune Escape and Immune-Mediated Pathogenesis during HDV Infection. Viruses 2022;14:198. [DOI: 10.3390/v14020198] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Dudareva S, Faber M, Zimmermann R, Bock CT, Offergeld R, Steffen G, Enkelmann J. [Epidemiology of viral hepatitis A to E in Germany]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2022. [PMID: 35029725 DOI: 10.1007/s00103-021-03478-8] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
20 Nkongolo S, Hollnberger J, Urban S. [Bulevirtide as the first specific agent against hepatitis D virus infections-mechanism and clinical effect]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2022. [PMID: 35028672 DOI: 10.1007/s00103-022-03486-2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Dunn R, Wetten A, McPherson S, Donnelly MC. Viral hepatitis in 2021: The challenges remaining and how we should tackle them. World J Gastroenterol 2022; 28(1): 76-95 [DOI: 10.3748/wjg.v28.i1.76] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Akbar SMF, Al Mahtab M, Yoshida O, Hiasa Y. Cellular and Molecular Mechanisms Underlying Scope and Limitation of Ongoing and Innovative Therapies for Treating Chronic Hepatitis B. Livers 2022;2:1-14. [DOI: 10.3390/livers2010001] [Reference Citation Analysis]
23 Altstetter SM, Quitt O, Pinci F, Hornung V, Lucko AM, Wisskirchen K, Jung S, Protzer U. Hepatitis-D Virus Infection Is Not Impaired by Innate Immunity but Increases Cytotoxic T-Cell Activity. Cells 2021;10:3253. [PMID: 34831475 DOI: 10.3390/cells10113253] [Reference Citation Analysis]
24 Knolle PA, Huang LR, Kosinska A, Wohlleber D, Protzer U. Improving Therapeutic Vaccination against Hepatitis B-Insights from Preclinical Models of Immune Therapy against Persistent Hepatitis B Virus Infection. Vaccines (Basel) 2021;9:1333. [PMID: 34835264 DOI: 10.3390/vaccines9111333] [Reference Citation Analysis]
25 Bogomolov PO, Ivashkin VT, Bueverov AO, Maev IV, Sagalova OI, Sleptsova SS, Yushuk ND, Gusev DA, Zhdanov KV, Chulanov VP. Efficacy and safety of bulevirtide in patients with chronic hepatitis D and compensated cirrhosis. Terapevticheskii arkhiv 2021;93:1290-9. [DOI: 10.26442/00403660.2021.11.201163] [Reference Citation Analysis]
26 Isaeva OV, Kyuregyan KK, Mikhailov MI. [Animal delta-like viruses (Kolmioviridae: Deltavirus) and the origin of the human hepatitis D virus (HDV)]. Vopr Virusol 2021;66:340-5. [PMID: 34738449 DOI: 10.36233/0507-4088-78] [Reference Citation Analysis]
27 Soriano V, Alvarez C, Edagwa B, de Mendoza C, Montoya N, Treviño A, Gendelman H. Ultra-long-acting (XLA) antivirals for chronic viral hepatitis. Int J Infect Dis 2021;114:45-50. [PMID: 34728344 DOI: 10.1016/j.ijid.2021.10.052] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
28 Niklasch M, Zimmermann P, Nassal M. The Hepatitis B Virus Nucleocapsid-Dynamic Compartment for Infectious Virus Production and New Antiviral Target. Biomedicines 2021;9:1577. [PMID: 34829806 DOI: 10.3390/biomedicines9111577] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Makbul C, Kraft C, Grießmann M, Rasmussen T, Katzenberger K, Lappe M, Pfarr P, Stoffer C, Stöhr M, Wandinger AM, Böttcher B. Binding of a Pocket Factor to Hepatitis B Virus Capsids Changes the Rotamer Conformation of Phenylalanine 97. Viruses 2021;13:2115. [PMID: 34834922 DOI: 10.3390/v13112115] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
30 Muhammad H, Zaffar D, Tehreem A, Ting P, Simsek C, Gokcan H, Gurakar A, Idilman R. HBV/HDV management after liver transplantation: Review. Journal of Liver Transplantation 2021;4:100046. [DOI: 10.1016/j.liver.2021.100046] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Salimi Alizei E, Hofmann M, Thimme R, Neumann-Haefelin C. Mutational escape from cellular immunity in viral hepatitis: variations on a theme. Curr Opin Virol 2021;50:110-8. [PMID: 34454351 DOI: 10.1016/j.coviro.2021.08.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Soriano V, Mendoza C, Barreiro P, Treviño A, Corral O. Envisioning a hepatitis delta cure with new antivirals. Future Microbiol 2021;16:927-30. [PMID: 34406066 DOI: 10.2217/fmb-2021-0177] [Reference Citation Analysis]
33 Heuschkel MJ, Baumert TF, Verrier ER. Cell Culture Models for the Study of Hepatitis D Virus Entry and Infection. Viruses 2021;13:1532. [PMID: 34452397 DOI: 10.3390/v13081532] [Reference Citation Analysis]